PT Darya-Varia Laboratoria Tbk

About PT Darya-Varia Laboratoria Tbk

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas. The company also exports its products to Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk is a subsidiary of Blue Sphere Singapore Pte. Ltd.

We are a long-established pharmaceutical company, committed in building a healthier Indonesia through market leading products services.

https://www.darya-varia.com

DVLA.JK Indonesia

2,520USD20 (+0.79%)

• At close Fri Oct 07 2022

Jakarta exchange

Sector: Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Location Indonesia, Jakarta

Grade: ADA

150,198,793 USD
MARKET CAP
30.303
PE
-0.035
BETA (5y)
65.010
EPS

Profits

for 5 years
29%
for 3 years
15%
for 2 years
9%
for last year
-13%
for this year
0%
PT Darya-Varia Laboratoria Tbk
© 2023 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.